In the last trading session, 2.7 million Aytu BioPharma Inc (NASDAQ:AYTU) shares changed hands as the company’s beta touched 0.29. With the company’s per share price at $2.13 changed hands at -$0.46 or -17.76% during last session, the market valuation stood at $13.14M. AYTU’s last price was a discount, traded about -57.28% off its 52-week high of $3.35. The share price had its 52-week low at $0.95, which suggests the last value was 55.4% up since then.
Aytu BioPharma Inc (NASDAQ:AYTU) trade information
Instantly AYTU was in red as seen at the end of in last trading. With action 70.40%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 25.29%, with the 5-day performance at 70.40% in the green. However, in the 30-day time frame, Aytu BioPharma Inc (NASDAQ:AYTU) is 108.82% up.
Aytu BioPharma Inc (AYTU) estimates and forecasts
Year-over-year growth is forecast to reach -12.53% down from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 19.61M. The company’s revenue for the corresponding quarters a year ago was 17.98M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 9.07%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 66.68%. The 2025 estimates are for Aytu BioPharma Inc earnings to increase by 136.36%.
AYTU Dividends
Aytu BioPharma Inc is expected to release its next quarterly earnings report in June.
Among Mutual Funds, the top two as of Mar 31, 2025 were Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 32.37 shares estimated at $68952.0 under it, the former controlled 0.52% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 0.45% of the shares, roughly 27.89 shares worth around $59401.0.
